EN
HI
Alembic Pharmaceuticals Share price
APLLTD
831.25
0.05 (0.01%)NSE
BSE
Last updated on 14 Aug, 2026 | 15:50 IST
Alembic Pharmaceuticals share price chart
Alembic Pharmaceuticals Share Key Metrics
Volume
86735.00
Market Cap
16339.31 CR
LTQ@LTP
3@831.25
ATP
827.56
Var Margin
15.77 %
Circuit Range
665-997.4
Delivery %
54.7 %
Value
7.18 CR
ASM/GSM
No
Market Lot
1
Summary
APLLTD stock price is ₹831.25 as of 14 Aug, 2026. The stock intraday movement has stayed between ₹815.40 and ₹834.40, while Alembic Pharmaceuticals share price 52 week high low is ₹635.80 & ₹1002.00.
In terms of trading activity, APLLTD share price has recorded a volume of 86,735 shares. The Alembic Pharmaceuticals has a market cap of ₹196563124. The stock’s Average Traded Price (ATP) stands at ₹827.56, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 3 @ ₹831.25.
The Alembic Pharmaceuticals upper circuit limit is ₹997.40 & The Alembic Pharmaceuticals lower circuit limit is ₹665.00, with a Value of ₹7.18 CR. The Delivery Percentage for the day is 54.7%.
Additionally, the share currently falls under the No framework, and trades with a market lot size of ₹1.
Alembic Pharmaceuticals Resistance and Support
Pivot 835.57
Resistance
First Resistance
843.14
Second Resistance
855.07
Third Resistance
862.64
Support
First Support
823.64
Second Support
816.07
Third Support
804.14
Alembic Pharmaceuticals Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Segment
Percent
Total Promoters
69.87%
Mutual Fund
8.73%
Insurance
6.89%
Foreign Institutional Investors
4.17%
Domestic Institutional Investors
0.33%
Retail
10.01%
Others
0%
Total Promoters
MAR '26
69.74%
JUN '26
69.87%
Alembic Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-04 | Quarterly Results |
| 2026-05-15 | Audited Results & Final Dividend |
| 2026-02-05 | Quarterly Results |
| 2025-11-04 | Quarterly Results & Others |
| 2025-08-05 | Quarterly Results & Others |
| 2025-05-06 | Audited Results & Final Dividend |
| 2025-02-03 | Quarterly Results & Others |
| 2024-11-07 | Quarterly Results |
| 2024-08-08 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-29 | 2026-07-29 | View More |
Alembic Pharmaceuticals News
Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Alembic Pharma reported strong Q1 FY27 consolidated financial results. Revenue increased 26% YoY to Rs. 2150 cr, and net profit grew 12% YoY to Rs. 173 cr, reflecting broad-based business growth.
Aug 04 2026 14:51:46
Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharma reported strong Q1 FY27 results, with revenue up 26% YoY to Rs.2,150 cr and net profit up 12% YoY to Rs.173 cr. EBITDA increased 21% YoY to Rs.523 cr.
Aug 04 2026 14:20:51
Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals received USFDA final approval for Prucalopride Tablets (1 mg and 2 mg). This approval allows the company to launch the drug in the US market, which has an estimated market size of US$100 million for chronic idiopathic constipation.
Jul 28 2026 13:23:22
Alembic Pharmaceuticals Ltd - 533573 - Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter Ended 30Th June, 2026.
Alembic Pharmaceuticals has scheduled a board meeting for August 4, 2026. The primary agenda is to consider and approve the unaudited financial results for the first quarter of fiscal year 2027, ending June 30, 2026.
Jul 24 2026 17:58:14
Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals' partner NATCO Pharma Limited secured USFDA tentative approval for Olaparib Tablets (100mg & 150mg), a drug with an estimated U.S. market size of $1.4 billion. Alembic will distribute the product in the U.S. while NATCO handles manufacturing.
Jul 18 2026 20:38:03
Read More
Alembic Pharmaceuticals Management
| Name | Position |
|---|---|
| Chirayu Amin | Chairman & CEO |
| Pranav Amin | Managing Director |
Alembic Pharmaceuticals Similar Stocks
Astrazeneca Pharma India Ltd.
7753.00
-39.50 (0.51%)
Poly Medicure Ltd.
1786.20
-26.60 (1.47%)
Onesource Specialty Pharma Ltd.
1559.20
-12.10 (0.77%)
Natco Pharma Ltd.
903.15
-48.55 (5.10%)
Cohance Lifesciences Ltd.
440.65
-3.55 (0.80%)
Dr. Agarwal's Health Care Ltd.
506.50
-2.00 (0.39%)
Shilpa Medicare Ltd.
822.00
14.95 (1.85%)
Vijaya Diagnostic Centre Ltd.
1474.10
-12.40 (0.83%)
Concord Biotech Ltd.
1451.30
-3.20 (0.22%)
Rainbow Children's Medicare Ltd.
1461.80
8.80 (0.61%)
Alembic Pharmaceuticals FAQs
The Buying Price of Alembic Pharmaceuticals share is 831.25 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Alembic Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Alembic Pharmaceuticals, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Alembic Pharmaceuticals shares is 23.57. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Alembic Pharmaceuticals shares is 2.8. Useful to assess the stock's value relative to its book value.
To assess Alembic Pharmaceuticals’s valuation compare Sector P/E, P/B which are 64.91 & 3.33 with sector averages, along with growth rates and financial metrics.
The Market Cap of Alembic Pharmaceuticals is 16339.31 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Alembic Pharmaceuticals share price is 1002.00 & 635.80. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Alembic Pharmaceuticals belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Invest in APLLTD
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC